LENZ Therapeutics
LENZ Therapeutics reported revenue of $19 million in fiscal 2025. Its operating margin was −477.5%. Free cash flow was −$70 million. The diluted share count rose 35.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
LENZ Therapeutics lost money in fiscal 2025: a net loss of $82 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 377 | 284 | 184 | 209 | 292 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 31.4x | 21.1x | 3.6x | 20.4x | 14.2x |
| Quick ratio | 31.4x | 21.1x | 3.6x | 20.4x | 14.1x |
Cash flow
Projections
Project LENZ Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What LENZ Therapeutics says to expect
- Full year 2027: operating expenses
The Company expects the reorganization to reduce projected 2027 annualized operating expenses by more than 50%, targeting approximately $70 million to $75 million in 2027 operating expenses, excluding stock-based compensation.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $365,553 of LENZ Therapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Evert B. SchimmelpenninkPresident, CEO and Secretary, Director | Bought | 28,089 | $8.95 | $251,397 | Form 4 |
| Mar 27, 2026 | Daniel R. ChevallardChief Financial Officer | Bought | 7,500 | $8.57 | $64,275 | Form 4 |
| Mar 27, 2026 | Jeffrey P. GeorgeDirector | Bought | 5,592 | $8.92 | $49,881 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −11.73 | 21.21 | 15.45 |
| Accruals ratio | −4.9% | 6.7% | −5.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Pass |
| F-score | — | — | — |
Compare
Put LENZ Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| LENZ Therapeutics | FY25 | — | −477.5% | −366.7% | — | — | — | |
| Alector | FY25 | −79.1% | −741.3% | −874.7% | — | — | 1 | Compare |
| MediWound | FY25 | −16.1% | −149.0% | −127.5% | — | — | — | Compare |
| uniQure | FY25 | −40.6% | −1,151.4% | −1,108.2% | — | — | 2 | Compare |
| Relay Therapeutics | FY25 | 53.4% | −1,971.6% | −1,536.1% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | 0 | 19 |
| Revenue growth | — | — | — | — | — | — |
| Gross profit | — | — | — | — | 0 | 19 |
| Research and development | 9 | 38 | 73 | 60 | 30 | 19 |
| Operating income | −14 | −60 | −106 | −72 | −59 | −91 |
| Net income | −68 | −71 | −101 | −70 | −50 | −82 |
| Diluted EPS (US$) | −29.93 | −2.45 | −1.84 | −35.71 | −2.34 | −2.85 |
| Diluted shares (millions) | 2 | 29 | 55 | 2 | 21 | 29 |
| Cash flow | ||||||
| Cash from operations | −9 | −53 | −88 | −60 | −59 | −69 |
| Capital expenditure | 2 | 6 | 7 | 0 | 0 | 1 |
| Free cash flow | −10 | −59 | −95 | −60 | −60 | −70 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 8 | 14 | 1 | 6 | 12 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 20 | 377 | 284 | 184 | 209 | 292 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 23 | 402 | 322 | 70 | 215 | 306 |
| Total liabilities | 32 | 18 | 26 | 20 | 11 | 22 |
| Shareholders' equity | −65 | 384 | −24 | −93 | 204 | 284 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | 97.8% |
| Operating margin | — | — | — | — | — | −477.5% |
| Net margin | — | — | — | — | — | −430.2% |
| Free cash flow margin | — | — | — | — | — | −366.7% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −44.4% | −56.2% | — | −89.4% | −33.6% |
| Return on assets | — | −33.3% | −27.9% | −35.7% | −34.8% | −31.5% |
| Net debt to EBITDA | — | — | — | — | — | — |